ArticleMolecular biology reports2025
Antibacterial effect and MexA efflux pump Inhibition by green-synthesized copper nanoparticles from Mentha piperita.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Manuka honey as a multifunctional therapeutic against Helicobacter pylori: from chemical profiling to in vitro potency and in vivo gastroprotective efficacy.BMC complementary medicine and therapies · 2026Article
- Green-synthesized metal oxide nanoparticles enhance the antibacterial activity of Portulaca oleracea through foliar nano-elicitation.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Cytotoxicity and antibacterial BioEffects of CuO-Zn nanoparticles synthesized from Lactobacillus helveticus yogurt isolates targeting RsbA gene expression.Scientific reports · 2026Article
- Green-Synthesized Copper and Copper Oxide Nanoparticles: Structural Characterization and Evaluation of Biological Activity.Antioxidants (Basel, Switzerland) · 2026Review
- Evaluation of antimicrobial and antibiofilm activities of peptide Impatiens balsamina-M1 and Zinc oxide nanoparticles against Helicobacter pylori.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa pose a significant worldwide health concern, mostly because of the ability of bacteria to expel antibiotics via efflux pumps such as MexA. The green synthesis of nanoparticles may offer a promising alternative to existing antimicrobial protocols. Hence, this study was designed to synthesize copper nanoparticles (Cu-NPs) from Mentha piperita (peppermint) leaf extract, assess their antibacterial activity, mainly against MDR Pseudomonas aeruginosa, and study efflux pump expression.
methodsCu-NPs were synthesized and characterized via UV-Vis spectroscopy, energy-dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD), and scanning electron microscopy (SEM). Antibacterial efficacy was assessed by agar well diffusion and minimum inhibitory concentration (MIC) assays against gram-positive and gram-negative bacteria. The effect of Cu-NPs on MexA gene expression in Pseudomonas aeruginosa was measured via real-time PCR. Cytotoxicity was tested in human white blood cells.
resultsThe green-synthesized Cu-NPs were spherical (particle sizes ~ 20-92 nm) and exhibited significant antibacterial activity, with the strongest effect detected against Pseudomonas aeruginosa (MIC: 500 µg/ml; inhibition zone > 20 mm). In addition, biogenic Cu-NP treatment downregulated MexA gene expression by approximately 50%, suggesting a role in reversing bacterial drug resistance. Cytotoxicity assays revealed tolerable safety at effective doses in vitro.
conclusionThis study demonstrated that Mentha piperita-mediated Cu-NPs have significant antibacterial activity and can reduce MexA efflux pump expression, highlighting their potential as adjuncts for managing MDR Pseudomonas aeruginosa infections. Hence, further in vitro and in vivo studies are warranted.
Indexed as
Identifiers
40960556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.